Nicole R. Hadas Akebia Therapeutics, Inc. (AKBA) insider trading activity

Nicole R. Hadas is SVP, Chief Legal Officer of Akebia Therapeutics, Inc.. Currently has a direct ownership of 651,243 shares of AKBA, which is worth approximately $1.2 Million. The most recent transaction as insider was on May 13, 2024, when has been sold 12,016 shares (Common Stock) at a price of $1.26 per share, resulting in proceeds of $15,140. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 651K

0% 3M change

24.2% 12M change

Total Value Held $1.2 Million

Nicole R. Hadas Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
May 13 2024	SELL Open market or private sale	$15,140 $1.26 p/Share	12,016 Reduced 1.81%	651,243 Common Stock
Feb 29 2024	SELL Open market or private sale	$9,438 $1.58 p/Share	5,974 Reduced 0.89%	663,259 Common Stock
Feb 27 2024	SELL Open market or private sale	$11,264 $1.52 p/Share	7,411 Reduced 1.1%	669,233 Common Stock
Jan 31 2024	BUY Grant, award, or other acquisition	-	149,300 Added 18.08%	676,644 Common Stock
May 25 2023	SELL Open market or private sale	$77,086 $1.22 p/Share	63,186 Reduced 10.75%	524,344 Common Stock
May 24 2023	BUY Grant, award, or other acquisition	-	200,000 Added 25.4%	587,530 Common Stock
May 12 2023	BUY Grant, award, or other acquisition	-	100,000 Added 20.51%	387,530 Common Stock
Mar 01 2023	SELL Open market or private sale	$11,469 $0.88 p/Share	13,034 Reduced 4.34%	287,530 Common Stock
Feb 27 2023	SELL Open market or private sale	$5,408 $0.81 p/Share	6,677 Reduced 2.17%	300,564 Common Stock
Mar 01 2022	SELL Open market or private sale	$31,480 $2.17 p/Share	14,507 Reduced 4.55%	304,241 Common Stock
Feb 28 2022	SELL Open market or private sale	$14,093 $2.15 p/Share	6,555 Reduced 2.41%	265,748 Common Stock
Feb 28 2022	BUY Grant, award, or other acquisition	-	50,000 Added 13.67%	315,748 Common Stock
Apr 01 2021	SELL Open market or private sale	$3,604 $3.4 p/Share	1,060 Reduced 0.39%	272,303 Common Stock
Mar 16 2021	BUY Grant, award, or other acquisition	-	10,192 Added 3.59%	273,363 Common Stock
Mar 01 2021	SELL Open market or private sale	$48,569 $3.4 p/Share	14,285 Reduced 5.15%	263,171 Common Stock
Feb 26 2021	BUY Grant, award, or other acquisition	-	62,000 Added 18.26%	277,456 Common Stock

NRH

Nicole R. Hadas

SVP, Chief Legal Officer

Cambridge, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells AKBA shares.

Notify only if

Value

Insider Trading

Get notified when an Akebia Therapeutics, Inc. insider buys or sells AKBA shares.

Notify only if

Operation

Value

Type

News

Receive news related to Akebia Therapeutics, Inc.

Track Activities on AKBA

Account